Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kantarjian, H. M.
Right arrow Articles by Keating, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kantarjian, H. M.
Right arrow Articles by Keating, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Fludarabine therapy in macroglobulinemic lymphoma

HM Kantarjian, R Alexanian, CA Koller, R Kurzrock and MJ Keating

Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

Fludarabine, a fluorinated analogue of adenine, was given to 11 patients with macroglobulinemic lymphoma, all but one having failed prior standard chemotherapy. Five patients (45%) responded with more than a 50% reduction of immunoglobulin M (IgM) tumor mass for a projected median duration of longer than 1 year. The onset of remission was usually slow, with a median tumor halving time of 5.2 months in responding patients, emphasizing the importance of repeated courses of treatment. Fludarabine is an important new agent effective against macroglobulinemic lymphoma, and should be evaluated further in combination with other active modalities.

Volume 75, Issue 10, pp. 1928-1931, 05/15/1990
Copyright © 1990 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. I. Chen
Treatment for Waldenstrom's macroglobulinemia
Ann. Onc., April 1, 2004; 15(4): 550 - 558.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Leblond, V. Levy, F. Maloisel, B. Cazin, J.-P. Fermand, J.-L. Harousseau, L. Remenieras, R. Porcher, M. Gardembas, G. Marit, et al.
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease
Blood, November 1, 2001; 98(9): 2640 - 2644.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, P. Panayiotidis, L. A. Moulopoulos, P. Sfikakis, and M. Dalakas
Waldenstrom’s Macroglobulinemia: Clinical Features, Complications, and Management
J. Clin. Oncol., January 5, 2000; 18(1): 214 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. M. Kolesar, A. K. Morris, and J. G. Kuhn
Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine
Journal of Oncology Pharmacy Practice, January 1, 1996; 2(3): 160 - 181.
[Abstract] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1990 by American Society of Hematology         Online ISSN: 1528-0020